Waxman/Hatch Debate Moves Forward: Generic Biologics Not Ruled Out
Executive Summary
A generic approval process for biological product is being recognized as one item for consideration in reform of the Waxman/Hatch Act by the law's key sponsor in the Senate.
You may also be interested in...
Alliance for Aging Research Waxman/Hatch Position Mirrors BIO Stance
The Alliance for Aging Research's support of patent restoration for clinical development time echoes BIO's position on Waxman/Hatch Act reform.
Alliance for Aging Research Waxman/Hatch Position Mirrors BIO Stance
The Alliance for Aging Research's support of patent restoration for clinical development time echoes BIO's position on Waxman/Hatch Act reform.
Product Life Cycle Limits May Level Playing Field For Generics - TCI's DiCicco
Legislation that would limit branded product life cycle management strategies could level the playing field for generic drug products, Technology Catalysts International President Richard DiCicco said at the International Generic Drug Forum Jan. 24 in Washington, D.C.